Core Viewpoint - The company Yipinhong (300723.SZ) has participated in the national procurement bidding for drugs whose agreements have expired, with 15 drug varieties proposed for selection in the upcoming procurement, which could positively impact its future operations and market presence [1] Group 1: Procurement Participation - The company's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., recently took part in the national procurement bidding organized by the procurement office for drugs with expired agreements [1] - The procurement office announced on February 10, 2026, that 15 drug varieties from the company are proposed for selection in this procurement [1] Group 2: Financial Impact - The total sales revenue for the 15 selected drug varieties is projected to be 228 million yuan for the year 2024, accounting for 15.75% of the company's total revenue for that year [1] - For the first three quarters of 2025, the projected sales revenue for these drugs is 157 million yuan (unaudited), representing 19.25% of the company's revenue for that period [1] Group 3: Future Implications - If procurement contracts are signed and implemented, it will further increase product sales, enhance market share, and improve the company's brand image, positively influencing its future business development [1]